Endocannabinoid overactivity and intestinal inflammation

Di Marzo, V.; Izzo, A. A.
October 2006
Gut;Oct2006, Vol. 55 Issue 10, p1373
Academic Journal
Cannabinoid receptors of type 1 and 2 (CB1 and CB2), endogenous ligands that activate them (endocannabinoids), and mechanisms for endocannabinoid biosynthesis and inactivation have been identified in the gastrointestinal system. Activation of CB1 receptors by endocannabinoids produces relaxation of the lower oesophageal sphincter and inhibition of gastric acid secretion, intestinal motility, and fluid stimulated secretion. However, stimulation of cannabinoid receptors impacts on gastrointestinal functions in several other ways. Recent data indicate that the endocannabinoid system in the small intestine and colon becomes over stimulated during inflammation in both animal models and human inflammatory disorders. The pathological significance of this ‘endocannabinoid overactivity’ and its possible exploitation for therapeutic purposes are discussed here.


Related Articles

  • Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease. Andrisani, G.; Guidi, L.; Papa, A.; Armuzzi, A. // European Review for Medical & Pharmacological Sciences;2012, Vol. 16 Issue 7, p890 

    Inflammatory bowel disease, Crohn's disease and ulcerative colitis, are immune- mediated disorders of unknown etiology that primarily affect the gastrointestinal tract. In addition, other organ systems can be involved such as joint/bones, skin, eyes, hepatobiliary tract, lungs and kidney....

  • Identifying the Ion Channels Responsible for Signaling Gastro-Intestinal Based Pain. Brierley, Stuart M.; Hughes, Patrick A.; Harrington, Andrea M.; Rychkov, Grigori Y.; Blackshaw, L. Ashley // Pharmaceuticals;Sep2010, Vol. 3 Issue 9, p2768 

    We are normally unaware of the complex signalling events which continuously occur within our internal organs. Most of us only become cognisant when sensations of hunger, fullness, urgency or gas arise. However, for patients with organic and functional bowel disorders pain is an unpleasant and...

  • Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease. Iwata, Shigeru; Saito, Kazuyoshi; Yamaoka, Kunihiro; Tsujimura, Shizuyo; Nawata, Masao; Hanami, Kentaro; Tanaka, Yoshiya // Modern Rheumatology (Springer Science & Business Media B.V.);Apr2011, Vol. 21 Issue 2, p184 

    It is often difficult to manage refractory gastrointestinal tract complications of Behçet's disease (entero-BD) by conventional therapy. In this study, we assessed the short- and long-term efficacy and safety of the combination therapy of infliximab, an anti-tumor-necrosis-factor (TNF)-α...

  • Complications of Tumor Necrosis Factor—α Blockade in Chronic Granulomatous Disease—Related Colitis. Uzel, Gulbu; Orange, Jordan S.; Poliak, Nina; Marciano, Beatriz E.; Heller, Theo; Holland, Steven M. // Clinical Infectious Diseases;12/15/2010, Vol. 51 Issue 12, p1429 

    Background. Chronic granulomatous disease (CGD) is a genetic disorder of the phagocyte NADPH oxidase, which predisposes patients to infections and inflammatory complications, including severe colitis. Management of CGD colitis is a challenge because standard immunosuppressive therapy increases...

  • Ulcerative Colitis Induces Changes on the Expression of the Endocannabinoid System in the Human Colonic Tissue. Marquéz, Lucia; Suárez, Juan; Iglesias, Mar; Bermudez-Silva, Francisco Javier; Rodríguez de Fonseca, Fernando; Andreu, Montserrat // PLoS ONE;2009, Vol. 4 Issue 9, p1 

    Background: Recent studies suggest potential roles of the endocannabinoid system in gastrointestinal inflammation. Although cannabinoid CB2 receptor expression is increased in inflammatory disorders, the presence and function of the remaining proteins of the endocannabinoid system in the colonic...

  • A place for TACE. van Deventer, S.J.H. // Gut;Jul2002, Vol. 51 Issue 1, p5 

    Comments on a study by J. Brynskov and colleagues, which examined tumor necrosis factor-alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Control of the production and secretion of TNA-alpha at multiple checkpoints; Physiological...

  • Tumour necrosis factor α converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Brynskov, J.; Foegh, P.; Pedersen, G.; Ellervik, C.; Kirkegaard, T.; Bingham, A.; Saermark, T. // Gut;Jul2002, Vol. 51 Issue 1, p37 

    Background: Anti-tumour necrosis factor α (TNF-α) antibodies are effective in Crohn's disease and perhaps ulcerative colitis but antigenicity and the high cost have raised interest in other strategies to block TNF-α. These include the TNF-α converting enzyme (TACE) which releases...

  • Lipopolysaccharide modulation of normal enterocyte turnover by toll-like receptors is mediated by endogenously produced tumour necrosis factors α. Ruemmele, F.M.; Beaulieu, J.F.; Dionne, S.; Levy, E.; Seidman, E.G.; Cerf-Bensussan, N.; Lentze, M.J. // Gut;Dec2002, Vol. 51 Issue 6, p842 

    Background: Circulating levels of endotoxin (or lipopolysaccharide (LPS)) and anti-endotoxin antibodies are increased in patients with inflammatory bowel disease, supporting the hypothesis of a role for endogenous bacterial products in the pathogenesis of these disorders. Aim: The aim of this...

  • Lower Esophageal Sphincter Response to Gastric Alkalinization. Castell, Donald O.; Levine, Stephen M. // Annals of Internal Medicine;Feb71, Vol. 74 Issue 2, p223 

    Evaluates the effect of different gastric alkalinizing agents on lower esophageal sphincter pressure. Description of the physiologic sphincter at the distal end of the esophagus; Measurement of intraluminal pressure; Analysis of gastric acidification and alkalinization.


Read the Article


Sign out of this library

Other Topics